# Offerpad Solutions Inc.: financial statements, quarterly

OPAD · Nasdaq · CIK 1825024 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/opad.md) · [Financials](/companies/opad/financials.md) · [Filings](/companies/opad/filings.md) · [Insiders](/companies/opad/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/opad/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [234](/filings/0000950170-24-120899.md) | [240 d](/filings/0001193125-26-067147.md) | [285](/filings/0000950170-25-063692.md) | [251](/filings/0000950170-25-102132.md) | [208](/filings/0001193125-25-262768.md) | [174 d](/filings/0001193125-26-067147.md) | [161](/filings/0001193125-26-197328.md) | [160](/filings/0001193125-26-330713.md) | [133](/filings/0001193125-25-262768.md) | [114 d](/filings/0001193125-26-067147.md) | [80.1](/filings/0001193125-26-197328.md) | [77.7](/filings/0001193125-26-330713.md) |
| Cost of revenue | $m | [210](/filings/0000950170-24-120899.md) | [224 d](/filings/0001193125-26-067147.md) | [263](/filings/0000950170-25-063692.md) | [229](/filings/0000950170-25-102132.md) | [191](/filings/0001193125-25-262768.md) | [164 d](/filings/0001193125-26-067147.md) | [150](/filings/0001193125-26-197328.md) | [146](/filings/0001193125-26-330713.md) | [123](/filings/0001193125-25-262768.md) | [106 d](/filings/0001193125-26-067147.md) | [74.5](/filings/0001193125-26-197328.md) | [70.5](/filings/0001193125-26-330713.md) |
| Gross profit | $m | [24.0](/filings/0000950170-24-120899.md) | [16.7 d](/filings/0001193125-26-067147.md) | [22.6](/filings/0000950170-25-063692.md) | [21.9](/filings/0000950170-25-102132.md) | [17.1](/filings/0001193125-25-262768.md) | [10.6 d](/filings/0001193125-26-067147.md) | [10.5](/filings/0001193125-26-197328.md) | [14.2](/filings/0001193125-26-330713.md) | [9.3](/filings/0001193125-25-262768.md) | [8.0 d](/filings/0001193125-26-067147.md) | [5.6](/filings/0001193125-26-197328.md) | [7.1](/filings/0001193125-26-330713.md) |
| Research and development | $m | [2.2](/filings/0000950170-24-120899.md) | [1.2 d](/filings/0001193125-26-067147.md) | [1.8](/filings/0000950170-25-063692.md) | [1.0](/filings/0000950170-25-102132.md) | [0.9](/filings/0001193125-25-262768.md) | [0.8 d](/filings/0001193125-26-067147.md) | [1.0](/filings/0001193125-26-197328.md) | [1.0](/filings/0001193125-26-330713.md) | [0.8](/filings/0001193125-25-262768.md) | [0.6 d](/filings/0001193125-26-067147.md) | [0.9](/filings/0001193125-26-197328.md) | [1.0](/filings/0001193125-26-330713.md) |
| Operating income | $m | [(19.5)](/filings/0000950170-24-120899.md) | [(11.3) d](/filings/0001193125-26-067147.md) | [(13.6)](/filings/0000950170-25-063692.md) | [(9.9)](/filings/0000950170-25-102132.md) | [(8.9)](/filings/0001193125-25-262768.md) | [(13.7) d](/filings/0001193125-26-067147.md) | [(11.5)](/filings/0001193125-26-197328.md) | [(7.8)](/filings/0001193125-26-330713.md) | [(6.7)](/filings/0001193125-25-262768.md) | [(7.3) d](/filings/0001193125-26-067147.md) | [(9.0)](/filings/0001193125-26-197328.md) | [(8.2)](/filings/0001193125-26-330713.md) |
| Interest expense | $m | [4.4](/filings/0000950170-23-057470.md) | [5.2 d](/filings/0000950170-24-021141.md) | [4.9](/filings/0000950170-24-053581.md) | [4.6](/filings/0000950170-24-090951.md) | [5.1](/filings/0001193125-25-262768.md) | [4.1 d](/filings/0001193125-26-067147.md) | [3.5](/filings/0001193125-26-197328.md) | [3.7](/filings/0001193125-26-330713.md) | [3.6](/filings/0001193125-25-262768.md) | [2.6 d](/filings/0001193125-26-067147.md) | [1.6](/filings/0001193125-26-197328.md) | [1.4](/filings/0001193125-26-330713.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-120899.md) | [(0.0) d](/filings/0001193125-26-067147.md) | [0.1](/filings/0000950170-25-063692.md) | [(0.1)](/filings/0000950170-25-102132.md) | [0.0](/filings/0001193125-25-262768.md) | [(0.1) d](/filings/0001193125-26-067147.md) | [0.0](/filings/0001193125-26-197328.md) | [0.0](/filings/0001193125-26-330713.md) | [0.4](/filings/0001193125-25-262768.md) | [(0.0) d](/filings/0001193125-26-067147.md) | [0.0](/filings/0001193125-26-197328.md) | [0.0](/filings/0001193125-26-330713.md) |
| Net income | $m | [(20.0)](/filings/0000950170-24-120899.md) | [(15.4) d](/filings/0001193125-26-067147.md) | [(17.5)](/filings/0000950170-25-063692.md) | [(13.8)](/filings/0000950170-25-102132.md) | [(13.5)](/filings/0001193125-25-262768.md) | [(17.3) d](/filings/0001193125-26-067147.md) | [(15.1)](/filings/0001193125-26-197328.md) | [(10.9)](/filings/0001193125-26-330713.md) | [(11.6)](/filings/0001193125-25-262768.md) | [(8.8) d](/filings/0001193125-26-067147.md) | [(10.1)](/filings/0001193125-26-197328.md) | [(9.3)](/filings/0001193125-26-330713.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0000950170-24-120899.md) | not reported | [(0.64)](/filings/0000950170-25-063692.md) | [(0.50)](/filings/0000950170-25-102132.md) | [(0.49)](/filings/0001193125-25-262768.md) | not reported | [(0.55)](/filings/0001193125-26-197328.md) | [(3.93)](/filings/0001193125-26-330713.md) | [(0.37)](/filings/0001193125-25-262768.md) | not reported | [(0.22)](/filings/0001193125-26-197328.md) | [(1.94)](/filings/0001193125-26-330713.md) |
| Basic EPS | $ per share | [(0.73)](/filings/0000950170-24-120899.md) | not reported | [(0.64)](/filings/0000950170-25-063692.md) | [(0.50)](/filings/0000950170-25-102132.md) | [(0.49)](/filings/0001193125-25-262768.md) | not reported | [(0.55)](/filings/0001193125-26-197328.md) | [(3.93)](/filings/0001193125-26-330713.md) | [(0.37)](/filings/0001193125-25-262768.md) | not reported | [(0.22)](/filings/0001193125-26-197328.md) | [(1.94)](/filings/0001193125-26-330713.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [106](/filings/0000950170-24-120899.md) | [76.0](/filings/0001193125-26-067147.md) | [68.6](/filings/0000950170-25-063692.md) | [56.9](/filings/0000950170-25-102132.md) | [48.5](/filings/0001193125-25-262768.md) | [43.0](/filings/0001193125-26-067147.md) | [30.8](/filings/0001193125-26-197328.md) | [22.7](/filings/0001193125-26-330713.md) | [31.0](/filings/0001193125-25-262768.md) | [26.5](/filings/0001193125-26-330713.md) | [40.8](/filings/0001193125-26-197328.md) | [33.1](/filings/0001193125-26-330713.md) |
| Current assets | $m | [413](/filings/0000950170-23-057470.md) | [372](/filings/0000950170-25-026788.md) | [353](/filings/0000950170-24-053581.md) | [391](/filings/0000950170-24-090951.md) | [323](/filings/0000950170-24-120899.md) | [294](/filings/0001193125-26-067147.md) | [255](/filings/0000950170-25-063692.md) | [250](/filings/0000950170-25-102132.md) | [206](/filings/0001193125-25-262768.md) | [132](/filings/0001193125-26-330713.md) | [127](/filings/0001193125-26-197328.md) | [138](/filings/0001193125-26-330713.md) |
| Total assets | $m | [422](/filings/0000950170-23-057470.md) | [380](/filings/0000950170-25-026788.md) | [370](/filings/0000950170-24-053581.md) | [407](/filings/0000950170-24-090951.md) | [338](/filings/0000950170-24-120899.md) | [313](/filings/0001193125-26-067147.md) | [274](/filings/0000950170-25-063692.md) | [268](/filings/0000950170-25-102132.md) | [223](/filings/0001193125-25-262768.md) | [155](/filings/0001193125-26-330713.md) | [150](/filings/0001193125-26-197328.md) | [160](/filings/0001193125-26-330713.md) |
| Current liabilities | $m | [305](/filings/0000950170-23-057470.md) | [276](/filings/0000950170-25-026788.md) | [272](/filings/0000950170-24-053581.md) | [320](/filings/0000950170-24-090951.md) | [263](/filings/0000950170-24-120899.md) | [251](/filings/0001193125-26-067147.md) | [226](/filings/0000950170-25-063692.md) | [230](/filings/0000950170-25-102132.md) | [156](/filings/0001193125-25-262768.md) | [88.8](/filings/0001193125-26-330713.md) | [76.4](/filings/0001193125-26-197328.md) | [95.7](/filings/0001193125-26-330713.md) |
| Total liabilities | $m | [307](/filings/0000950170-23-057470.md) | [278](/filings/0000950170-25-026788.md) | [282](/filings/0000950170-24-053581.md) | [329](/filings/0000950170-24-090951.md) | [274](/filings/0000950170-24-120899.md) | [265](/filings/0001193125-26-067147.md) | [240](/filings/0000950170-25-063692.md) | [243](/filings/0000950170-25-102132.md) | [184](/filings/0001193125-25-262768.md) | [117](/filings/0001193125-26-330713.md) | [104](/filings/0001193125-26-197328.md) | [123](/filings/0001193125-26-330713.md) |
| Shareholders' equity | $m | [115](/filings/0000950170-24-120899.md) | [102](/filings/0001193125-26-067147.md) | [88.1](/filings/0000950170-25-102132.md) | [77.6](/filings/0001193125-25-262768.md) | [64.7](/filings/0001193125-25-262768.md) | [47.7](/filings/0001193125-26-330713.md) | [34.2](/filings/0001193125-26-330713.md) | [24.5](/filings/0001193125-26-330713.md) | [39.9](/filings/0001193125-25-262768.md) | [38.2](/filings/0001193125-26-330713.md) | [45.8](/filings/0001193125-26-330713.md) | [37.3](/filings/0001193125-26-330713.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(94.5) d](/filings/0000950170-24-120899.md) | [(15.3) d](/filings/0001193125-26-067147.md) | [2.4](/filings/0000950170-25-063692.md) | [(54.4) d](/filings/0000950170-25-102132.md) | [39.6 d](/filings/0001193125-25-262768.md) | [33.2 d](/filings/0001193125-26-067147.md) | [(10.2)](/filings/0001193125-26-197328.md) | [(13.5) d](/filings/0001193125-26-330713.md) | [40.0 d](/filings/0001193125-25-262768.md) | [50.5 d](/filings/0001193125-26-067147.md) | [9.0](/filings/0001193125-26-197328.md) | [(25.9) d](/filings/0001193125-26-330713.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-120899.md) | [0.0 d](/filings/0001193125-26-067147.md) | [0.4](/filings/0000950170-25-063692.md) | [0.0 d](/filings/0000950170-25-102132.md) | [0.9 d](/filings/0001193125-25-262768.md) | [4.2 d](/filings/0001193125-26-067147.md) | [1.0](/filings/0001193125-26-197328.md) | [0.1 d](/filings/0001193125-26-330713.md) | [0.0 d](/filings/0001193125-25-262768.md) | [0.0 d](/filings/0001193125-26-067147.md) | [0.0](/filings/0001193125-26-197328.md) | [0.0 d](/filings/0001193125-26-330713.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.5](/filings/0000950170-23-057470.md) | [23.7](/filings/0000950170-24-053581.md) | [27.3](/filings/0000950170-24-090951.md) | [27.3](/filings/0000950170-24-120899.md) | [27.3](/filings/0000950170-25-063692.md) | [27.4](/filings/0000950170-25-102132.md) | [27.4](/filings/0001193125-25-262768.md) | [27.6](/filings/0001193125-26-197328.md) | [2.8](/filings/0001193125-26-330713.md) | [31.3](/filings/0001193125-25-262768.md) | [46.2](/filings/0001193125-26-197328.md) | [4.8](/filings/0001193125-26-330713.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,832,749 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-330713.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.